Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?

No abstract is available for this paper.

• Publication year

  1979

• Venue

  Biochemical Pharmacology

• Publication date

  1979-03-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0006-2952(79)90376-9PMID 454488
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action.

  1978cited by this paper
• Deprenyl in Parkinson's disease.

  1977cited by this paper
• Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

  1977cited by this paper
• Inhibition by clorgyline and deprenyl of the different forms of monoamine oxidase in rat liver mitochondria.

  1976cited by this paper
• Monoamine oxidase inhibitors and L-dopa.

  1970cited by this paper
• Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

  1965cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Protective Effect of Selegiline (R-deprenyl) in Aminoglycoside-Induced Hearing Loss

  2025cites this paper
• THE DISCOVERY OF THE ENHANCER REGULATION IN THE MAMMALIAN BRAIN AND THE DEVELOPMENT OF THE SYNTHETIC ENHANCER SUBSTANCES A chance to significantly improve the quality and prolong the duration of human life

  2016cites this paper
• Development of transdermal drug delivery system of selegiline

  2015cites this paper
• Aktivitätsbasierte Sondenmoleküle zur Untersuchung der Aktivität Flavin-abhängiger Oxidasen und zum Zielprotein-Profiling von Monoaminooxidase-Inhibitoren

  2012cites this paper
• Activity-Based Probes for Studying the Activity of Flavin-Dependent Oxidases and for the Protein Target Profiling of Monoamine Oxidase Inhibitors

  2012cites this paper
• The pharmacology of selegiline.

  2011influential citation
• Selegiline transdermal system: current awareness and promise.

  2007cites this paper
• Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects

  2006cites this paper
• Deprenyl: from chemical synthesis to neuroprotection.

  2006cites this paper
• Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.

  2006cites this paper
• The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients

  2005cites this paper
• Biphasic Effects of Selegiline on Striatal Dopamine: Lack of Effect on Methamphetamine-Induced Dopamine Depletion

  2004cites this paper
• Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

  2003cites this paper
• Daily transdermal administration of selegiline to guinea‐pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues

  2003cites this paper
• Transdermal selegiline: targeted effects on monoamine oxidases in the brain.

  2003cites this paper
• Changes in vascular alpha1‐ and alpha2‐adrenoceptor responsiveness by selegiline treatment

  2001cites this paper
• Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro.

  2001cites this paper
• Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.

  2001cites this paper
• Adverse Drug Reactions to Selegiline: A Review of the French Pharmacovigilance Database

  2000cites this paper
• MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?

  2000cites this paper
• L-Deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors

  1999cites this paper
• L-Deprenyl stimulates the release of catecholamines in the rat medial basal hypothalamus in vivo.

  1999cites this paper
• Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal

  1999cites this paper
• Anticonvulsant efficacy of L-deprenyl (selegiline) during chronic treatment in mice: continuous versus discontinuous administration.

  1998cites this paper
• Idiopathic generalised epilepsy in adults manifested by phantom absences, generalised tonic-clonic seizures, and frequent absence status.

  1998cites this paper
• A case of pandysautonomia with associated sensory ganglionopathy

  1998cites this paper
• Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease

  1998cites this paper
• MAO — The Mother of all Amine Oxidases

  1998cites this paper
• Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset.

  1998cites this paper
• Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not males.

  1997cites this paper
• Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease

  1997cites this paper
• Cognitive recovery instead of decline after acute encephalitis: a prospective follow up study

  1997cites this paper
• Autonomic eVects of selegiline: possible cardiovascular toxicity in Parkinson's disease

  1997cites this paper
• Pharmacology of selegiline

  1996cites this paper
• Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo

  1996cites this paper
• Selective inhibitors of monoamine oxidase (MAO‐A and MAO‐B) as probes of its catalytic site and mechanism

  1995cites this paper
• Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats.

  1995cites this paper
• The effect of 6-months l-deprenyl administration on pineal MAO-A and MAO-B activity and on the content of melatonin and related indoles in aged female Fisher 344N rats.

  1994cites this paper
• Pharmacokinetic aspects of l‐deprenyl (selegiline) and its metabolites *

  1994cites this paper
• Repeated administrations of (-)-deprenyl increase [3H]MK801 binding in rat brain and antagonize the impairment of passive avoidance conditioning induced by N-methyl-D-aspartate receptor antagonists.

  1994cites this paper
• Biochemical actions of l‐deprenyl (selegiline) *

  1994cites this paper
• Behaviour of (-)-deprenyl and its analogues.

  1994cites this paper
• Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.

  1994cites this paper
• Medicinal Chemistry of Present and Future MAO-B Inhibitors

  1993cites this paper
• Pharmacology of Monoamine Oxidase Type B Inhibitors

  1993cites this paper
• Effect of Chronic Administration of Antidepressants on α2-Adrenoceptors in the Locus Coeruleus and Its Projection Fields in Rat Brain Determined by Quantitative Autoradiography

  1993cites this paper
• The effect ofl-deprenyl on behavior, cognitive function, and biogenic amines in the dog

  1993cites this paper
• Chronic effects of monoamine oxidase-B inhibitors on the behaviour of aged mice.

  1993cites this paper
• Monoamine oxidase inhibition byl-deprenyl depends on both sex and route of administration in the rat

  1993cites this paper
• Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography.

  1992cites this paper
• The molecular pharmacology of L-deprenyl.

  1992cites this paper
• MAO-B-Hemmer

  1992cites this paper
• A review of the pharmacology of selegiline

  1991cites this paper
• Amine Oxidases and Their Impact on Neurobiology

  1990cites this paper
• Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP.

  1990cites this paper
• Chromatographic studies on the binding, action and metabolism of (-)-deprenyl.

  1990cites this paper
• The effect of (-) deprenyl (selegiline) on different behavioral changes induced by dopamine agonists in the rat.

  1988cites this paper
• Serotonin-mediated behavior in rats chronically treated with (-) deprenyl.

  1988cites this paper
• The effect of various MAO-B inhibitors on rabbit arterial strip response to tyramine.

  1988cites this paper
• Influence of repeated administration of (-)deprenyl on serotonin syndrome in rats

  1988cites this paper
• R-(—)-Deprenyl (Selegilin, Movergan®) fördert die Aktivität der nigro-striären dopaminergen Neuronen

  1988cites this paper
• The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.

  1986cites this paper
• Monoamine oxidase inhibitor activity of selective and non-selective inhibitors: an in vivo dose-response and time-course study.

  1986cites this paper
• The effect of repeated administration of (-) deprenyl on the phenylethylamine-induced stereotypy in rats.

  1986cites this paper
• Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.

  1986cites this paper
• Role of B-Type Monoamine Oxidase Inhibition in the Treatment of Parkinson’s Disease

  1986cites this paper
• Effects of antidepressant drug combinations on cortical 5-HT2 receptors and wet-dog shakes in rats.

  1985cites this paper
• Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors.

  1985cites this paper
• Selective inhibitors of monoamine oxidase A and B: Biochemical, pharmacological, and clinical properties

  1984cites this paper
• The (-)-deprenyl actions on beta-adrenergic receptors require the integrity of brain serotonergic axon terminals.

  1984cites this paper
• Pharmacokinetic aspects of deprenyl effects.

  1984cites this paper
• Deprenyl (selegiline): the history of its development and pharmacological action

  1983cites this paper
• (-)-Deprenyl a selective MAO "B' inhibitor, increases [3H]imipramine binding and decreases beta-adrenergic receptor function.

  1983cites this paper
• The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.

  1982cites this paper
• Inhibition of rat liver monoamine oxidase by alpha-methyl- and N-propargyl-amine derivatives.

  1982cites this paper
• The action of (-) deprenyl on monoamine turnover rate in rat brain.

  1982cites this paper
• Inhibition of rat liver monoamine oxidase by α-methyl- and N-propargyl-amine derivatives

  1982cites this paper
• The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J‐508: their properties and applications

  1981cites this paper
• The effect of monoamine oxidase A and B inhibitors on rat serum prolactin.

  1981cites this paper
• STRUCTURE-ACTIVITY RELATIONSHIP OF SELECTIVE INHIBITORS OF MAO-B

  1980cites this paper
• SELECTIVE INHIBITORS OF MAO-B WITH DIFFERENT PHARMACOLOGICAL PROFILES

  1980cites this paper
• Drug Interactions

  1980cites this paper